Revolutionizing cardiac diagnostics with the CADScor®System, an AI-driven tool for rapid and non-invasive CAD detection.
Revolutionizing cardiac diagnostics with the CADScor®System, an AI-driven tool for rapid and non-invasive CAD detection.
Product: CADScor System — acoustics + AI point-of-care diagnostic aid for coronary artery disease
Regulatory status: CE-marked and FDA De Novo–cleared
Clinical use: Used in tens of thousands of patient assessments (40k–47k reported)
Public listing: Listed on Nasdaq First North (ticker: ACARIX) and cross‑traded on OTCQB (ACIXF)
Founding: Spin-out from Aalborg University/Coloplast; founded 2009
Early cardiac diagnostics and coronary artery disease risk stratification
2009
Medical devices / Medtech
SEK 140000000
IPO proceeds reported as SEK 140M; company listed on public exchange (Dec 19, 2016)
Latest pre-IPO funding recorded on Nov 11, 2016
“Life Science Invest Fund 1 participated in and helped guarantee a subsequent rights issue; recent insider share purchases by CEO Aamir Mahmood reported.”